Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial
The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. In a multi-center randomized co...
Saved in:
Published in | Journal of Korean medical science Vol. 34; no. 14; pp. e110 - 13 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
The Korean Academy of Medical Sciences
15.04.2019
대한의학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1011-8934 1598-6357 1598-6357 |
DOI | 10.3346/jkms.2019.34.e110 |
Cover
Abstract | The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system.
In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation.
The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%;
= 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days;
= 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.
PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.
ClinicalTrials.gov Identifier: NCT02202941. |
---|---|
AbstractList | The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system.BACKGROUNDThe objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system.In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation.METHODSIn a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation.The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.RESULTSThe two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.CONCLUSIONPCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.ClinicalTrials.gov Identifier: NCT02202941.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT02202941. Background: The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. Methods: In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost- minimization analysis of PCT-guided antibiotic discontinuation. Results: The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6–10 days vs. 14 days; IQR, 12–21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT- guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.Conclusion: PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes. KCI Citation Count: 2 The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation. The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis. PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes. ClinicalTrials.gov Identifier: NCT02202941. |
Author | Cho, Songhee Suh, Jae Kyung Hong, Sang-Bum Lee, Sang-Min Jang, Eun Jin Kim, Jae Yeol Ryu, Ho Geol Lee, Hyun Joo Jeon, Kyeongman |
AuthorAffiliation | 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea 7 Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 10 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 5 Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 9 Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea 1 Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea 3 National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea 8 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospit |
AuthorAffiliation_xml | – name: 6 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea – name: 7 Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – name: 1 Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea – name: 5 Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 4 Department of Information Statistics, Andong National University, Andong, Korea – name: 8 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea – name: 9 Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea – name: 3 National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea – name: 10 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Kyeongman orcidid: 0000-0002-4822-1772 surname: Jeon fullname: Jeon, Kyeongman organization: Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea – sequence: 2 givenname: Jae Kyung orcidid: 0000-0002-9804-2983 surname: Suh fullname: Suh, Jae Kyung organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea – sequence: 3 givenname: Eun Jin orcidid: 0000-0002-9137-9815 surname: Jang fullname: Jang, Eun Jin organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea., Department of Information Statistics, Andong National University, Andong, Korea – sequence: 4 givenname: Songhee orcidid: 0000-0003-2192-7182 surname: Cho fullname: Cho, Songhee organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea – sequence: 5 givenname: Ho Geol orcidid: 0000-0001-8952-6049 surname: Ryu fullname: Ryu, Ho Geol organization: Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 7 givenname: Sang-Bum orcidid: 0000-0002-4424-7457 surname: Hong fullname: Hong, Sang-Bum organization: Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 8 givenname: Hyun Joo orcidid: 0000-0002-1223-4387 surname: Lee fullname: Lee, Hyun Joo organization: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 9 givenname: Jae Yeol orcidid: 0000-0003-3631-4610 surname: Kim fullname: Kim, Jae Yeol organization: Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea – sequence: 10 givenname: Sang-Min orcidid: 0000-0002-1388-9318 surname: Lee fullname: Lee, Sang-Min organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30977312$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002457335$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9Uk1v1DAUtFAR_YAfwAX52B6y2LHjJByQVlsolYq6Wpaz5XVeqFvH3toOUvkV_GSc3VIBB07vyW9mnu2ZY3TgvAOEXlMyY4yLt7d3Q5yVhLYzxmdAKXmGjmjVNoVgVX2Qe0Jp0bSMH6LjGG8JKauqZC_QISNtXTNaHqGfy-C1stok74wrLkbTQYfXAVQawCXsHT4fg0omN77Hc5fMxvhkNF7fQFDbB6xchxc-Jmwc_gLbabTM-EyO-HS5uj6fn73DCn8ebTLFIh9DwKtM8oP5ARPVpeCt3W01yr5Ez3tlI7x6rCfo68cP68Wn4ur64nIxvyo0ZywVjFagNa1K3rG64SA2HWt7IgRRQhNSA2lFpTjnhDUVpzXTuhEbIXoNXFDQ7ASd7XVd6OWdNtIrs6vfvLwLcr5aX0re5L-tRMa-32O342aATudHBGXlNphBhYcd8--JMzdZ57sUXBBKJoHTR4Hg70eISQ4marBWOfBjlGVJ2uwba8oMffPnrqclvy3LALoH6OBjDNA_QSiRUyzkFAs5xUIyLqdYZE79DycbvjM1X9fY_zB_AWJAvs8 |
CitedBy_id | crossref_primary_10_4103_picr_picr_298_23 crossref_primary_10_1016_j_jointm_2022_10_001 crossref_primary_10_1002_phar_2834 crossref_primary_10_1080_14787210_2021_1932462 crossref_primary_10_3346_jkms_2019_34_e122 crossref_primary_10_1016_j_cca_2021_01_004 crossref_primary_10_1080_23744235_2022_2037701 crossref_primary_10_3947_ic_2022_0170 crossref_primary_10_1080_14737159_2023_2242782 crossref_primary_10_1080_10408363_2021_1975637 crossref_primary_10_1177_11772719241298197 crossref_primary_10_36106_ijsr_5217256 crossref_primary_10_1097_CCM_0000000000006366 crossref_primary_10_5124_jkma_2019_62_12_638 crossref_primary_10_23736_S0031_0808_19_03809_6 crossref_primary_10_1080_14737159_2020_1782193 crossref_primary_10_3389_fmed_2023_1080007 crossref_primary_10_1097_QCO_0000000000000707 crossref_primary_10_1186_s40560_025_00776_0 crossref_primary_10_5005_jp_journals_10071_24326 crossref_primary_10_1007_s40274_019_5868_8 crossref_primary_10_1002_ams2_70037 crossref_primary_10_3390_antibiotics11030367 crossref_primary_10_1097_CCE_0000000000000571 |
Cites_doi | 10.1586/eri.10.25 10.1186/1471-2334-13-158 10.1007/s00423-008-0432-1 10.3111/13696998.2015.1064934 10.1164/rccm.200708-1238OC 10.1097/CCM.0b013e31821201a5 10.1093/jac/dku497 10.1007/s001340050644 10.1016/S0140-6736(15)00474-2 10.1164/rccm.201408-1483OC 10.1001/archinternmed.2012.770 10.1136/bmjopen-2012-002186 10.1097/MD.0000000000002100 10.1097/CCM.0b013e31821e8791 10.1097/CCM.0b013e31827e83af 10.1016/S0140-6736(09)61879-1 10.1186/cc7903 10.1016/S1473-3099(16)00053-0 10.1016/S1473-3099(14)70780-7 10.1164/rccm.200512-1922OC 10.1016/j.diagmicrobio.2013.03.027 10.1097/CCM.0000000000001294 10.3947/ic.2014.46.2.84 10.1097/CCM.0000000000002255 10.1086/315214 10.1001/archinternmed.2011.318 10.1002/jhm.988 10.1093/cid/cix179 10.1017/ice.2014.60 |
ContentType | Journal Article |
Copyright | 2019 The Korean Academy of Medical Sciences. 2019 The Korean Academy of Medical Sciences. 2019 The Korean Academy of Medical Sciences |
Copyright_xml | – notice: 2019 The Korean Academy of Medical Sciences. – notice: 2019 The Korean Academy of Medical Sciences. 2019 The Korean Academy of Medical Sciences |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3346/jkms.2019.34.e110 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1598-6357 |
EndPage | 13 |
ExternalDocumentID | oai_kci_go_kr_ARTI_4801956 PMC6460106 30977312 10_3346_jkms_2019_34_e110 |
Genre | Randomized Controlled Trial Multicenter Study Journal Article |
GrantInformation_xml | – fundername: Ministry of Health and Welfare grantid: NA14-003 – fundername: ; grantid: NA14-003 |
GroupedDBID | --- 29K 2WC 3O- 5-W 53G 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c433t-315ecc1524d3784e6bd39f0660a6c007e0965a44403854173cc86b66fce461ec3 |
IEDL.DBID | M48 |
ISSN | 1011-8934 1598-6357 |
IngestDate | Sun Mar 09 07:53:44 EDT 2025 Thu Aug 21 13:18:30 EDT 2025 Thu Jul 10 18:10:26 EDT 2025 Thu Apr 03 07:00:54 EDT 2025 Tue Jul 01 01:45:01 EDT 2025 Thu Apr 24 23:07:45 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 14 |
Keywords | Economics Biomarkers Sepsis Anti-Bacterial Agents Intensive Care Unit Calcitonin |
Language | English |
License | 2019 The Korean Academy of Medical Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c433t-315ecc1524d3784e6bd39f0660a6c007e0965a44403854173cc86b66fce461ec3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Kyeongman Jeon and Jae Kyung Suh contributed equally to this work. |
ORCID | 0000-0002-1388-9318 0000-0002-4822-1772 0000-0002-1223-4387 0000-0002-9804-2983 0000-0001-8952-6049 0000-0003-3631-4610 0000-0002-4424-7457 0000-0002-9137-9815 0000-0003-2192-7182 0000-0002-1170-8042 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2019.34.e110 |
PMID | 30977312 |
PQID | 2209598382 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_4801956 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6460106 proquest_miscellaneous_2209598382 pubmed_primary_30977312 crossref_primary_10_3346_jkms_2019_34_e110 crossref_citationtrail_10_3346_jkms_2019_34_e110 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-04-15 |
PublicationDateYYYYMMDD | 2019-04-15 |
PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of Korean medical science |
PublicationTitleAlternate | J Korean Med Sci |
PublicationYear | 2019 |
Publisher | The Korean Academy of Medical Sciences 대한의학회 |
Publisher_xml | – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
References | de Jong (10.3346/jkms.2019.34.e110_ref13) 2016; 16 Hochreiter (10.3346/jkms.2019.34.e110_ref7) 2009; 13 Jensen (10.3346/jkms.2019.34.e110_ref14) 2011; 39 Kip (10.3346/jkms.2019.34.e110_ref30) 2015; 18 File (10.3346/jkms.2019.34.e110_ref3) 2012; 7 Van Boeckel (10.3346/jkms.2019.34.e110_ref16) 2014; 14 Svoboda (10.3346/jkms.2019.34.e110_ref5) 2007; 54 Christ-Crain (10.3346/jkms.2019.34.e110_ref19) 2006; 174 Schuetz (10.3346/jkms.2019.34.e110_ref23) 2011; 171 Howard (10.3346/jkms.2019.34.e110_ref25) 2015; 70 Deliberato (10.3346/jkms.2019.34.e110_ref11) 2013; 76 Gogos (10.3346/jkms.2019.34.e110_ref21) 2000; 181 World Health Organization (10.3346/jkms.2019.34.e110_ref17) 2014 Chu (10.3346/jkms.2019.34.e110_ref26) 2017; 64 Laxminarayan (10.3346/jkms.2019.34.e110_ref4) 2016; 387 Heyland (10.3346/jkms.2019.34.e110_ref28) 2011; 39 Meisner (10.3346/jkms.2019.34.e110_ref32) 1998; 24 Harrison (10.3346/jkms.2019.34.e110_ref29) 2015; 36 Dellinger (10.3346/jkms.2019.34.e110_ref1) 2013; 41 Albrich (10.3346/jkms.2019.34.e110_ref27) 2012; 172 Rhodes (10.3346/jkms.2019.34.e110_ref24) 2017; 45 Annane (10.3346/jkms.2019.34.e110_ref10) 2013; 3 Yong (10.3346/jkms.2019.34.e110_ref18) 2014; 46 Schroeder (10.3346/jkms.2019.34.e110_ref8) 2009; 394 Thomas (10.3346/jkms.2019.34.e110_ref2) 2015; 43 10.3346/jkms.2019.34.e110_ref31 Shehabi (10.3346/jkms.2019.34.e110_ref12) 2014; 190 Yoon (10.3346/jkms.2019.34.e110_ref20) 2015; 94 Bouadma (10.3346/jkms.2019.34.e110_ref9) 2010; 375 Hohn (10.3346/jkms.2019.34.e110_ref15) 2013; 13 Nobre (10.3346/jkms.2019.34.e110_ref6) 2008; 177 Schuetz (10.3346/jkms.2019.34.e110_ref22) 2010; 8 30977318 - J Korean Med Sci. 2019 Apr 15;34(14):e122 |
References_xml | – volume: 8 start-page: 575 issue: 5 year: 2010 ident: 10.3346/jkms.2019.34.e110_ref22 publication-title: Expert Rev Anti Infect Ther doi: 10.1586/eri.10.25 – volume: 13 start-page: 158 issue: 1 year: 2013 ident: 10.3346/jkms.2019.34.e110_ref15 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-13-158 – volume-title: Antimicrobial Resistance: Global Report on Surveillance year: 2014 ident: 10.3346/jkms.2019.34.e110_ref17 – volume: 394 start-page: 221 issue: 2 year: 2009 ident: 10.3346/jkms.2019.34.e110_ref8 publication-title: Langenbecks Arch Surg doi: 10.1007/s00423-008-0432-1 – volume: 18 start-page: 944 issue: 11 year: 2015 ident: 10.3346/jkms.2019.34.e110_ref30 publication-title: J Med Econ doi: 10.3111/13696998.2015.1064934 – volume: 177 start-page: 498 issue: 5 year: 2008 ident: 10.3346/jkms.2019.34.e110_ref6 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200708-1238OC – volume: 39 start-page: 1792 issue: 7 year: 2011 ident: 10.3346/jkms.2019.34.e110_ref28 publication-title: Crit Care Med doi: 10.1097/CCM.0b013e31821201a5 – volume: 70 start-page: 1245 issue: 4 year: 2015 ident: 10.3346/jkms.2019.34.e110_ref25 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dku497 – volume: 24 start-page: 680 issue: 7 year: 1998 ident: 10.3346/jkms.2019.34.e110_ref32 publication-title: Intensive Care Med doi: 10.1007/s001340050644 – volume: 387 start-page: 168 issue: 10014 year: 2016 ident: 10.3346/jkms.2019.34.e110_ref4 publication-title: Lancet doi: 10.1016/S0140-6736(15)00474-2 – volume: 190 start-page: 1102 issue: 10 year: 2014 ident: 10.3346/jkms.2019.34.e110_ref12 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201408-1483OC – volume: 172 start-page: 715 issue: 9 year: 2012 ident: 10.3346/jkms.2019.34.e110_ref27 publication-title: Arch Intern Med doi: 10.1001/archinternmed.2012.770 – volume: 3 start-page: e002186 issue: 2 year: 2013 ident: 10.3346/jkms.2019.34.e110_ref10 publication-title: BMJ Open doi: 10.1136/bmjopen-2012-002186 – volume: 94 start-page: e2100 issue: 46 year: 2015 ident: 10.3346/jkms.2019.34.e110_ref20 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000002100 – volume: 39 start-page: 2048 issue: 9 year: 2011 ident: 10.3346/jkms.2019.34.e110_ref14 publication-title: Crit Care Med doi: 10.1097/CCM.0b013e31821e8791 – volume: 41 start-page: 580 issue: 2 year: 2013 ident: 10.3346/jkms.2019.34.e110_ref1 publication-title: Crit Care Med doi: 10.1097/CCM.0b013e31827e83af – volume: 375 start-page: 463 issue: 9713 year: 2010 ident: 10.3346/jkms.2019.34.e110_ref9 publication-title: Lancet doi: 10.1016/S0140-6736(09)61879-1 – volume: 54 start-page: 359 issue: 74 year: 2007 ident: 10.3346/jkms.2019.34.e110_ref5 publication-title: Hepatogastroenterology – volume: 13 start-page: R83 issue: 3 year: 2009 ident: 10.3346/jkms.2019.34.e110_ref7 publication-title: Crit Care doi: 10.1186/cc7903 – volume: 16 start-page: 819 issue: 7 year: 2016 ident: 10.3346/jkms.2019.34.e110_ref13 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(16)00053-0 – volume: 14 start-page: 742 issue: 8 year: 2014 ident: 10.3346/jkms.2019.34.e110_ref16 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70780-7 – volume: 174 start-page: 84 issue: 1 year: 2006 ident: 10.3346/jkms.2019.34.e110_ref19 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200512-1922OC – volume: 76 start-page: 266 issue: 3 year: 2013 ident: 10.3346/jkms.2019.34.e110_ref11 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2013.03.027 – volume: 43 start-page: 2527 issue: 12 year: 2015 ident: 10.3346/jkms.2019.34.e110_ref2 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000001294 – volume: 46 start-page: 84 issue: 2 year: 2014 ident: 10.3346/jkms.2019.34.e110_ref18 publication-title: Infect Chemother doi: 10.3947/ic.2014.46.2.84 – volume: 45 start-page: 486 issue: 3 year: 2017 ident: 10.3346/jkms.2019.34.e110_ref24 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000002255 – volume: 181 start-page: 176 issue: 1 year: 2000 ident: 10.3346/jkms.2019.34.e110_ref21 publication-title: J Infect Dis doi: 10.1086/315214 – volume: 171 start-page: 1322 issue: 15 year: 2011 ident: 10.3346/jkms.2019.34.e110_ref23 publication-title: Arch Intern Med doi: 10.1001/archinternmed.2011.318 – volume: 7 start-page: S22 issue: Suppl 1 year: 2012 ident: 10.3346/jkms.2019.34.e110_ref3 publication-title: J Hosp Med doi: 10.1002/jhm.988 – ident: 10.3346/jkms.2019.34.e110_ref31 – volume: 64 start-page: 1509 issue: 11 year: 2017 ident: 10.3346/jkms.2019.34.e110_ref26 publication-title: Clin Infect Dis doi: 10.1093/cid/cix179 – volume: 36 start-page: 265 issue: 3 year: 2015 ident: 10.3346/jkms.2019.34.e110_ref29 publication-title: Infect Control Hosp Epidemiol doi: 10.1017/ice.2014.60 – reference: 30977318 - J Korean Med Sci. 2019 Apr 15;34(14):e122 |
SSID | ssj0025523 |
Score | 2.319008 |
Snippet | The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with... Background: The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e110 |
SubjectTerms | Aged Anti-Bacterial Agents - economics Anti-Bacterial Agents - therapeutic use Biomarkers - analysis Cost of Illness Critical Illness Female Hospital Mortality Humans Intensive Care Units Kaplan-Meier Estimate Male Middle Aged Original Procalcitonin - analysis Sepsis - drug therapy Sepsis - mortality Sepsis - pathology Single-Blind Method 의학일반 |
Title | Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30977312 https://www.proquest.com/docview/2209598382 https://pubmed.ncbi.nlm.nih.gov/PMC6460106 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002457335 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Korean Medical Science, 2019, 34(14), , pp.1-13 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9NAEF7OE8Qv4vlaX8oqflAhpdudbFJBpNx53inV42zhvi3bza6G9jaatuDdr7if7EySFitF8FMI2ReS2ck8szPzLGMvpKnKKVHTvDER4ttulJrYRwIcmL7B_2HlKA4_q6MxfDyLz3bY6nir5gPOt7p2dJ7UuJx1fv28eIcK_5Y8TkkRyuk5EW-LfkdCxwkquLqOhkmRLzaEdVABwXOvzrcXIkIzDXWQc_sQG2bqWij9NgT6dyLlH5bp8Da71UBKPqjXwB7bceEOuzFsguZ32RUVA5iZRd0NeYg-LPPMZXy0yjDnReAHy3oh8MLzQaAykgIH46OacoCbkPH9Yr7geeBfKQ3G8pOaj3XOX56cfjkYvHrDDa-KeSPaL3YlP8VOxXl-6ahrlQ4_q2bF9X6PjQ_fj_aPouYghsiClAv8T8coabT0kMkkBacmmex7BCtdoyyCDEcUMgYAKMwIIpHWpmqilLcOlHBW3me7oQjuIePeeQOZAdH3BA582pPSJskEkZ-NjVEt1l19d20blnI6LGOm0VshUWkSlSZRaQmaRNVir9ddftQUHf9q_ByFqac210SsTddvhZ6WGt2HY01cOugwttizlaw1ahuFUExwxRKH6tG-aSrTXos9qGW_nlN2EUtLgU-SjVWxbkATbj4J-feK0VtBFe5-9D9v8pjdpFuKbIn4CdtdlEv3FAHSYtJG1-D4U7vaXmhXKvAbrisPpQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Procalcitonin-Guided+Treatment+on+Duration+of+Antibiotic+Therapy+and+Cost+in+Septic+Patients+%28PRODA%29%3A+a+Multi-Center+Randomized+Controlled+Trial&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Jeon%2C+Kyeongman&rft.au=Suh%2C+Jae+Kyung&rft.au=Jang%2C+Eun+Jin&rft.au=Cho%2C+Songhee&rft.date=2019-04-15&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=34&rft.issue=14&rft_id=info:doi/10.3346%2Fjkms.2019.34.e110&rft.externalDBID=n%2Fa&rft.externalDocID=10_3346_jkms_2019_34_e110 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |